[An aortic insufficiency diagnosed under cabergoline].

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Hyperprolactinemia is often treated with dopamine agonists like cabergoline.
• Dopamine agonists have been associated with valvular heart disease, though typically at higher doses.
• Previous exposure to dopamine agonists is a known risk factor for drug-induced valvulopathy.

Observation:

• A 53-year-old woman developed restrictive aortic insufficiency while on low-dose cabergoline for hyperprolactinemia.
• The patient had a history of exposure to other dopamine agonists prior to cabergoline treatment.

Findings:

• The temporal relationship between cabergoline initiation and the onset of aortic insufficiency suggests a potential causal link.
• Restrictive aortic insufficiency was diagnosed despite the patient receiving a low dose of cabergoline.
• The patient's history of prior dopamine agonist exposure may increase susceptibility to cabergoline-induced valvulopathy.

Implications:

• This case highlights the potential for low-dose cabergoline to cause valvular heart disease.
• Routine echocardiographic monitoring may be warranted for patients treated with cabergoline, particularly those with a history of dopamine agonist use.
• The possibility of iatrogenic valvulopathy, including from dopamine agonists, should be considered in the diagnosis of restrictive valvulopathy.